Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $5.8 million.

  • Aytu Biopharma's Other Operating Expenses fell 12.37% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.0 million, marking a year-over-year increase of 26.48%. This contributed to the annual value of $32.9 million for FY2025, which is 27.50% up from last year.
  • Per Aytu Biopharma's latest filing, its Other Operating Expenses stood at $5.8 million for Q3 2025, which was down 58.71% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Other Operating Expenses peaked at $14.4 million during Q4 2022, and registered a low of -$53.1 million during Q1 2022.
  • Moreover, its 3-year median value for Other Operating Expenses was $6.3 million (2024), whereas its average is $8.1 million.
  • Per our database at Business Quant, Aytu Biopharma's Other Operating Expenses tumbled by 422.75% in 2021 and then soared by 224.98% in 2022.
  • Aytu Biopharma's Other Operating Expenses (MRQ) stood at -$11.5 million in 2021, then surged by 224.98% to $14.4 million in 2022, then plummeted by 57.49% to $6.1 million in 2023, then rose by 0.93% to $6.2 million in 2024, then fell by 6.89% to $5.8 million in 2025.
  • Its Other Operating Expenses stands at $5.8 million for Q3 2025, versus $14.0 million for Q2 2025 and $6.1 million for Q1 2025.